Switch theme
Sign up to access all valuation multiples
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.
2001
63
LTM Revenue $17.0M
LTM EBITDA $3.0M
$79.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gentian Diagnostics has a last 12-month revenue (LTM) of $17.0M and a last 12-month EBITDA of $3.0M.
In the most recent fiscal year, Gentian Diagnostics achieved revenue of $14.9M and an EBITDA of $2.9M.
Gentian Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gentian Diagnostics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $17.0M | XXX | $14.9M | XXX | XXX | XXX |
| Gross Profit | $9.8M | XXX | $8.1M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 54% | XXX | XXX | XXX |
| EBITDA | $3.0M | XXX | $2.9M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $2.0M | XXX | $1.5M | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $3.5M | XXX | $4.4M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 30% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Gentian Diagnostics's stock price is NOK 58 (or $6).
Gentian Diagnostics has current market cap of NOK 894M (or $87.4M), and EV of NOK 810M (or $79.2M).
See Gentian Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $79.2M | $87.4M | XXX | XXX | XXX | XXX | $0.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Gentian Diagnostics has market cap of $87.4M and EV of $79.2M.
Gentian Diagnostics's trades at 5.3x EV/Revenue multiple, and 27.3x EV/EBITDA.
Equity research analysts estimate Gentian Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gentian Diagnostics has a P/E ratio of 24.8x.
See valuation multiples for Gentian Diagnostics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $87.4M | XXX | $87.4M | XXX | XXX | XXX |
| EV (current) | $79.2M | XXX | $79.2M | XXX | XXX | XXX |
| EV/Revenue | 4.7x | XXX | 5.3x | XXX | XXX | XXX |
| EV/EBITDA | 26.1x | XXX | 27.3x | XXX | XXX | XXX |
| EV/EBIT | 39.0x | XXX | 51.5x | XXX | XXX | XXX |
| EV/Gross Profit | 8.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.8x | XXX | 19.7x | XXX | XXX | XXX |
| EV/FCF | 92.5x | XXX | 323.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGentian Diagnostics's last 12 month revenue growth is 29%
Gentian Diagnostics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Gentian Diagnostics's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gentian Diagnostics's rule of X is 90% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Gentian Diagnostics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 29% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 60% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 90% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gentian Diagnostics acquired XXX companies to date.
Last acquisition by Gentian Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Gentian Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Gentian Diagnostics founded? | Gentian Diagnostics was founded in 2001. |
| Where is Gentian Diagnostics headquartered? | Gentian Diagnostics is headquartered in Norway. |
| How many employees does Gentian Diagnostics have? | As of today, Gentian Diagnostics has 63 employees. |
| Who is the CEO of Gentian Diagnostics? | Gentian Diagnostics's CEO is Ms. Hilja Ibert. |
| Is Gentian Diagnostics publicy listed? | Yes, Gentian Diagnostics is a public company listed on OSL. |
| What is the stock symbol of Gentian Diagnostics? | Gentian Diagnostics trades under GENT ticker. |
| When did Gentian Diagnostics go public? | Gentian Diagnostics went public in 2016. |
| Who are competitors of Gentian Diagnostics? | Similar companies to Gentian Diagnostics include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Gentian Diagnostics? | Gentian Diagnostics's current market cap is $87.4M |
| What is the current revenue of Gentian Diagnostics? | Gentian Diagnostics's last 12 months revenue is $17.0M. |
| What is the current revenue growth of Gentian Diagnostics? | Gentian Diagnostics revenue growth (NTM/LTM) is 29%. |
| What is the current EV/Revenue multiple of Gentian Diagnostics? | Current revenue multiple of Gentian Diagnostics is 4.7x. |
| Is Gentian Diagnostics profitable? | Yes, Gentian Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gentian Diagnostics? | Gentian Diagnostics's last 12 months EBITDA is $3.0M. |
| What is Gentian Diagnostics's EBITDA margin? | Gentian Diagnostics's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Gentian Diagnostics? | Current EBITDA multiple of Gentian Diagnostics is 26.1x. |
| What is the current FCF of Gentian Diagnostics? | Gentian Diagnostics's last 12 months FCF is $0.9M. |
| What is Gentian Diagnostics's FCF margin? | Gentian Diagnostics's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Gentian Diagnostics? | Current FCF multiple of Gentian Diagnostics is 92.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
